Zealand Pharma A/S Stock Price Today (NSE: ZEAL)

Zealand Pharma A/S

73.554.05 (5.22%)
Market Closed

Fundamental Score

...

Zealand Pharma A/S Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Zealand Pharma A/S share price today is 73.55, down 5.22% on NSE/BSE as of 22 September 2026. Zealand Pharma A/S (ZEAL) is a Small-cap company in the Logistics Solution Provider sector with a market capitalisation of 87.31 (Cr). The 52-week high for ZEAL share price is 124.75 and the 52-week low is 55.90. At a P/E ratio of 7.83x, ZEAL is currently trading below its industry average P/E of 25.01x. The company has a Return on Equity (ROE) of 12.85% and a debt-to-equity ratio of 0.22.

Zealand Pharma A/S Share Price Chart — NSE/BSE Historical Performance

No data
High
93.55
Low
60.60
Volume
9.6K
Change
+42.70%

Zealand Pharma A/S share price chart: 42.70% return over the past month. 52-week high ₹124.75, 52-week low ₹55.90.

Zealand Pharma A/S — Last 10 Trading Days

DateOpenHighLowCloseVolume
78.2078.2073.2073.553.00K (Cr)
75.5078.0075.5077.606.00K (Cr)
75.3082.5075.3080.007.20K (Cr)
75.0075.0075.0075.00600.00 (Cr)
80.0080.0075.2077.503.60K (Cr)
77.0083.5077.0083.507.20K (Cr)
78.0078.0074.1576.551.80K (Cr)
87.3087.5080.5580.556.00K (Cr)
91.0091.0085.0087.106.00K (Cr)
85.0093.5585.0091.4039.00K (Cr)

Zealand Pharma A/S — Last 12 Months Price History

MonthOpenHighLowCloseChange
62.5093.5561.5073.55+17.68%
63.5066.4560.6062.50-1.57%
65.0068.6563.6065.60+0.92%
71.1071.1065.0068.00-4.36%
70.9072.4562.1070.90+0.00%
59.9597.0059.9570.90+18.27%
70.8077.0055.9057.30-19.07%
71.5090.4071.2579.50+11.19%
90.0595.0072.0072.00-20.04%
100.05101.8091.5094.00-6.05%
108.00121.4099.15102.95-4.68%
116.45120.90101.00106.95-8.16%

Returns & Performance

Poor

Return on Equity (ROE)

12.85%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.57%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

7.47%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Zealand Pharma A/S Valuation Check

Excellent

Price to Earnings (P/E)

7.83x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

25.01x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

73.40%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

2.44%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

21.15%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-42.16%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

36.35%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-22.69%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

43.69%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.22x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

8.23x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-14.20 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Zealand Pharma A/S Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ZEAL across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Excellent ROCE Performance (16.57%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 7.83 vs Industry: 25.01)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (21.15%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Consistent Growth Track Record (36.35% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (43.69% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.22)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (8.23x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (73.40%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Revenue Contraction (-42.16%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Weak Earnings Growth (-22.69% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Negative Free Cash Flow (₹-14.20 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 2.44%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Zealand Pharma A/S vs Logistics Solution Provider Peers

Peer Comparison - Logistics Solution Provider

Compare Zealand Pharma A/S with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
55.8/100
74
₹87.31
7.8
Average
12.85%
Average
16.57%
Good
0.2
Excellent
43.69%
Excellent
36.35%
Excellent
0.00%
45.5/100
510
₹38865.47
31.2
Average
9.81%
Poor
12.46%
Average
0.0
Excellent
19.71%
Excellent
7.15%
Good
1.87%
32.6/100
450
₹33720.72
360.2
Average
1.60%
Poor
2.58%
Poor
0.0
Excellent
19.76%
Excellent
23.57%
Excellent
0.00%
48.8/100
4926
₹11688.92
40.7
Average
0.00%
Poor
17.25%
Good
0.1
Excellent
19.34%
Excellent
13.31%
Good
0.51%
63.1/100
869
₹6691.69
14.6
Average
19.48%
Good
16.53%
Good
0.1
Excellent
25.60%
Excellent
11.90%
Good
1.08%
33.8/100
125
₹5504.62
85.4
Average
5.96%
Poor
10.25%
Average
0.5
Good
28.84%
Excellent
9.68%
Good
0.00%
51.9/100
289
₹5053.14
18.9
Average
21.27%
Excellent
18.83%
Good
0.4
Excellent
39.35%
Excellent
12.81%
Good
3.26%
58.5/100
1630
₹4249.49
31.7
Average
36.01%
Excellent
36.69%
Excellent
0.9
Good
98.76%
Excellent
111.16%
Excellent
0.00%
35.6/100
403
₹3996.58
108.0
Average
0.28%
Poor
7.48%
Poor
0.0
Excellent
-40.22%
Poor
16.48%
Excellent
0.64%
45.8/100
25
₹3834.78
69.1
Average
3.42%
Poor
2.40%
Poor
0.3
Excellent
27.21%
Excellent
-10.08%
Poor
0.00%
48/100
54
₹2685.59
11.0
Average
11.37%
Average
11.08%
Average
0.1
Excellent
22.07%
Excellent
13.40%
Good
3.38%

Zealand Pharma A/S PE Ratio History

Historical price-to-earnings ratio for ZEAL — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20237.40₹215.0029x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Zealand Pharma A/S Dividend History

Annual cash dividends paid by ZEAL — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20241.33 Cr
FY 20210.02 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Zealand Pharma A/S Quarterly Performance

Latest quarterly metrics for ZEAL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-42.16%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

21.15%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

36.35%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

43.69%

Compounded annual net profit growth over 5 years

Zealand Pharma A/S Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ZEAL — calculated from daily price history

79RSI 14
Overbought — RSI 79

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
67
▲ Price above SMA 50 — Short-term bullish
SMA 200
82
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
5K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Zealand Pharma A/S Financial Statements

Annual income statement, balance sheet and cash flow for Zealand Pharma A/S (ZEAL) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Zealand Pharma A/S

Loading latest quarterly results...

About ZEAL (Zealand Pharma A/S)

Zealand Pharma A/S (ZEAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Logistics Solution Provider sector wi...th a current market capitalisation of ₹87.31 (Cr). Zealand Pharma A/S has delivered a Return on Equity (ROE) of 12.85% and a ROCE of 16.57%. The debt-to-equity ratio stands at 0.22, reflecting the company's capital structure. Investors tracking ZEAL share price can monitor key metrics including P/E ratio, promoter holding of 73.40%, and quarterly earnings growth.

Company Details

Symbol:ZEAL
Industry:Logistics Solution Provider
Sector:Logistics Solution Provider
Website:N/A

ZEAL Share Price: Frequently Asked Questions

What is the current share price of Zealand Pharma A/S?

Zealand Pharma A/S (ZEAL) trades at ₹73.55 on NSE. Market cap ₹87.31 (Cr). Educational data only.

What is the P/E ratio of Zealand Pharma A/S?

Zealand Pharma A/S has a P/E of 7.83x vs industry average 25.01x.

What is the Bull Run score for Zealand Pharma A/S?

Zealand Pharma A/S has a Bull Run score of 55.8/100 based on 25+ financial parameters.

Does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Zealand Pharma A/S?

Zealand Pharma A/S has ROE of 12.85%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Zealand Pharma A/S?

Zealand Pharma A/S has debt-to-equity of 0.22.

Is Zealand Pharma A/S a good investment?

Bull Run gives Zealand Pharma A/S a score of 55.8/100. This is not investment advice — consult a SEBI-registered advisor.